Atherosclerotic plaque growth: presence of stimulatory fibrin degradation products
- PMID: 1723306
Atherosclerotic plaque growth: presence of stimulatory fibrin degradation products
Abstract
Focal smooth muscle cell proliferation is widely perceived as a key event in the formation of stenosing atherosclerotic lesions, but the stimuli for this remain uncertain. Soluble extracts of human aortic intima from proliferative gelatinous and transitional lesions, as well as surface encrusted thrombi, have been shown by us to be mitogenic for the chick chorioallantoic membrane (CAM). They have also been shown to stimulate increase in vascularity of the CAM. When active samples were passed through anti-albumin and anti-whole-serum affinity columns, mitogenic activity in the unabsorbed, fibrin related antigen fraction remained close to the original whole extract level. In contrast, when the unabsorbed fractions from anti-whole-serum columns were passed through an antifibrinogen affinity columns, the activity was reduced to insignificant levels. Similarly, whole extracts lost activity after passing through an antifibrinogen column. This has been taken one stage further by dividing the unabsorbed fraction from an anti-whole-serum column into two equal volumes and passing one half through an antifibrinogen fragment D affinity column, and the other through an antifibrinogen fragment E affinity column. The activity of the unabsorbed fraction from the fragment D column remained the same, but that from the fragment E column was significantly reduced. Most of the fibrin degradation products (FbDP) in lesion extracts are derived from fibrin, not fibrinogen, and clotting out fibrinogen and fragment X with thrombin did not remove the activity. Whole extracts of atherosclerotic lesions clotted on the CAM surface as has previously been shown with plasma.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Presence of growth-stimulating fibrin degradation products containing fragment E in human atherosclerotic plaques.Atherosclerosis. 1993 Nov;103(2):159-69. doi: 10.1016/0021-9150(93)90259-w. Atherosclerosis. 1993. PMID: 7507326
-
Factors relevant to stimulatory activity of fibrin degradation products in vivo.Blood Coagul Fibrinolysis. 1990 Oct;1(4-5):517-20. doi: 10.1097/00001721-199010000-00029. Blood Coagul Fibrinolysis. 1990. PMID: 1723307
-
Fibrin degradation products in growth stimulatory extracts of pathological lesions.Blood Coagul Fibrinolysis. 1993 Feb;4(1):113-5. Blood Coagul Fibrinolysis. 1993. PMID: 8457637
-
Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis.Clin Haematol. 1986 May;15(2):355-70. Clin Haematol. 1986. PMID: 3524931 Review.
-
Fibrinogen and atherosclerosis.Wien Klin Wochenschr. 1993;105(15):417-24. Wien Klin Wochenschr. 1993. PMID: 8379153 Review.
Cited by
-
Fibrinogen/fibrin in atherogenesis.Eur J Epidemiol. 1992 May;8 Suppl 1:83-7. doi: 10.1007/BF00145356. Eur J Epidemiol. 1992. PMID: 1387095 Review.
-
Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury.Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):245-9. doi: 10.1073/pnas.93.1.245. Proc Natl Acad Sci U S A. 1996. PMID: 8552614 Free PMC article.
-
Demonstration of a novel circulating anti-prostacyclin receptor antibody.Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8779-82. doi: 10.1073/pnas.94.16.8779. Proc Natl Acad Sci U S A. 1997. PMID: 9238054 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources